DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity

Abstract

Get full access to this article

View all access options for this article.

References

Brown

JWL

Coles

Horakova

, et al. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA 2019; 321(2): 175–187, https://pubmed.ncbi.nlm.nih.gov/30644981/ (accessed 29 June 2021).

Mahad

Trapp

Lassmann

Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol 2015; 14(2): 183–193, https://pubmed.ncbi.nlm.nih.gov/25772897/ (accessed 28 June 2021).

Lublin

Reingold

Cohen

, et al. Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology 2014; 83(3): 278–286, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4117366/ (accessed 28 June 2021).

Hawker

O’Connor

Freedman

, et al. Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009; 66(4): 460–471, https://pubmed.ncbi.nlm.nih.gov/19847908/ (accessed 28 June 2021).

Montalban

Hauser

Kappos

, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 2017; 376(3): 209–220.

Wolinsky

Arnold

Bar-Or

, et al. Efficacy of ocrelizumab in patients with PPMS with and without T1 gadolinium-enhancing lesions at baseline in a Phase III, placebo-controlled trial. Mult Scler J 2016; 22(1_suppl): 2–84, https://journals.sagepub.com/doi/full/10.1177/1352458516631279 (accessed 28 June 2021).

Weideman

Tapia-Maltos

Johnson

, et al. Meta-analysis of the age-dependent efficacy of multiple sclerosis treatments. Front Neurol 2017; 8: 577, www.frontiersin.org (accessed 29 June 2021).

Lorscheider

Kuhle

Izquierdo

, et al. Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: A cohort study. Eur J Neurol 2019; 26(2): 363–370, https://onlinelibrary.wiley.com/doi/full/10.1111/ene.13824 (accessed 28 June 2021).

Kalincik

Lizak

Malpas

, et al. Association of sustained immunotherapy with disability outcomes in patients with active secondary progressive multiple sclerosis. JAMA Neurol 2020; 77(11): 1398–1407, https://jamanetwork.com/ (accessed 28 June 2021).

10.

Feinstein

Freeman

AC.

Treatment of progressive multiple sclerosis: What works, what does not, and what is needed. Lancet Neurol 2015; 14(2): 194–207, https://pubmed.ncbi.nlm.nih.gov/25772898/ (accessed 28 June 2021).

DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity – No

Abstract

Get full access to this article

References